Showing 6681-6690 of 8883 results for "".
- Dr. Daniel Siegel Joins MedX's Medical Advisory Boardhttps://practicaldermatology.com/news/dr-daniel-siegel-joins-medxs-medical-advisory-board/2457754/Daniel Siegel, MD, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the American Academy of Dermatology has joined the Medical Advisory Board of MedX Health Corp. “Daniel’s academic and practical business experience is impres
- FDA Approves Lilly's Taltz for Label Update to Treat Psoriasis Involving the Genital Areahttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-label-update-to-treat-psoriasis-involving-the-genital-area/2457755/The FDA has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. Eli Lilly and Company's Taltz is the first treatment FDA approved for moderate-to-severe plaque psoriasis that includes such data in its label. Taltz was
- EWG: Two-Thirds of Sunscreen Products Offer Poor Protection or Have Worrisome Ingredientshttps://practicaldermatology.com/news/ewg-two-thirds-of-sunscreen-products-offer-poor-protection-or-have-worrisome-ingredients/2457756/The Environmental Working Group (EWG) released its 12th annual Guide to Sunscreens, rating the safety and efficacy of more than 1,000 sunscreens, moisturizers and lip balms that advertise sun protection, and found
- FDA Greenlights Restylane Lyft for Hand Rejuvenationhttps://practicaldermatology.com/news/fda-greenlights-restylane-lyft-for-hand-rejuvenation/2457757/The US Food and Drug Administration has approved Restylane Lyft for use on the dorsal hands of people older than 21, making it the first hyaluronic acid (HA) injectable gel approved for this use. Radiesse (Calcium Hydroxylapatite) is also approved for the correction of lost
- Biotin Supplements Caused Misleading Test Results, Almost Led to an Unnecessary Procedurehttps://practicaldermatology.com/news/biotin-supplements-caused-misleading-test-results-almost-led-to-an-unnecessary-procedure/2457758/A new case report in the Journal of the Endocrine Society documents how a patient's use of a biotin supplement, caused her to have clinically misleading test results, whic
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- ASDS: Skin Cancer Treatment Ranks as Most-Performed Procedure of 2017https://practicaldermatology.com/news/asds-skin-cancer-treatment-ranks-as-most-performed-procedure-of-2017/2457761/The American Society for Dermatologic Surgery (ASDS) members performed nearly 12 million medically necessary and cosmetic procedures in 2017 – over 10 percent more than 2016 and doubling since 2012. For the sixth year in a row, the 2017 ASDS Survey on Dermatologic Procedures reveale
- Dupixent Improves Moderate-to-Severe Atopic Dermatitis in Adolescentshttps://practicaldermatology.com/news/dupixent-improves-moderate-to-severe-atopic-dermatitis-in-adolescents/2457764/DUPIXENT (dupilumab) performed well in a Phase 3 Trial of inadequately controlled moderate-to-severe atopic dermatitis in adolescents, Regeneron and Sanofi report. In the trial, treatment with DUPIXENT as monotherapy significantly improved measures of overall disease severity, skin c
- FDA Frowns on Evolus' Botox Rivalhttps://practicaldermatology.com/news/fda-frowns-on-evolus-botox-rival/2457763/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat